论文部分内容阅读
目的探讨联合检测癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)和细胞角蛋白19片段抗原(CYFRA21-1)在肺癌诊断中的价值。方法583例肺部疾病患者(其中肺癌508例,肺部良性病变75例),采用罗氏电化学发光免疫系统检测其血清CEA、CYFRA21-1、NSE肿瘤标志物水平。结果肺癌患者血清肿瘤标志物均高于肺良性病变中(P<0.05),敏感性分别为CEA 48.6%(247/508)、CYFRA21-155.3%(281/508)和NSE 53.5%(272/508),联合检测敏感性为82.9%(421/508)。结论CEA、NSE和CY-FRA21-1对肺癌诊断中有一定价值。联合检测对各类型肺癌有较高的敏感性和特异性。
Objective To investigate the value of combined detection of carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and cytokeratin 19 fragment antigen (CYFRA21-1) in the diagnosis of lung cancer. Methods 583 patients with pulmonary diseases (including 508 cases of lung cancer and 75 cases of benign lung disease) were enrolled in this study. Serum CEA, CYFRA21-1 and NSE tumor markers were detected by Roche electrochemiluminescence immunoassay. Results The serum tumor markers in patients with lung cancer were significantly higher than those in benign pulmonary lesions (P <0.05). The sensitivity of CEA was 48.6% (247/508), CYFRA21-155.3% (281/508) and NSE 53.5% (272/508) ), The combined detection sensitivity was 82.9% (421/508). Conclusion CEA, NSE and CY-FRA21-1 have certain value in the diagnosis of lung cancer. Joint detection of all types of lung cancer have a higher sensitivity and specificity.